{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T02:48:25Z","timestamp":1793155705933,"version":"4.5.0"},"reference-count":183,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["RO1s AR057643"],"award-info":[{"award-number":["RO1s AR057643"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["CA191317"],"award-info":[{"award-number":["CA191317"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.autrev.2021.102761","type":"journal-article","created":{"date-parts":[[2021,1,18]],"date-time":"2021-01-18T22:30:44Z","timestamp":1611009044000},"page":"102761","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"title":["Engineered antigen-specific regulatory T cells for autoimmune skin conditions"],"prefix":"10.1016","volume":"20","author":[{"given":"Zhussipbek","family":"Mukhatayev","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yekaterina O.","family":"Ostapchuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deyu","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I. Caroline","family":"Le Poole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2021.102761_bb0005","doi-asserted-by":"crossref","first-page":"911","DOI":"10.2217\/imt.11.79","article-title":"Tregs in immunotherapy: opportunities and challenges","volume":"3","author":"Chen","year":"2011","journal-title":"Immunotherapy"},{"key":"10.1016\/j.autrev.2021.102761_bb0010","doi-asserted-by":"crossref","first-page":"Fso186","DOI":"10.4155\/fsoa-2016-0095","article-title":"The development of T cells from stem cells in mice and humans","volume":"3","author":"Famili","year":"2017","journal-title":"Future Sci OA"},{"key":"10.1016\/j.autrev.2021.102761_bb0015","doi-asserted-by":"crossref","first-page":"805875","DOI":"10.1155\/2012\/805875","article-title":"The role of different subsets of regulatory T cells in immunopathogenesis of rheumatoid arthritis","volume":"2012","author":"Gol-Ara","year":"2012","journal-title":"Arthritis"},{"key":"10.1016\/j.autrev.2021.102761_bb0020","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/cmi.2015.44","article-title":"Type 1 regulatory T cells: a new mechanism of peripheral immune tolerance","volume":"12","author":"Zeng","year":"2015","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.autrev.2021.102761_bb0025","doi-asserted-by":"crossref","first-page":"233","DOI":"10.3389\/fimmu.2018.00233","article-title":"Regulatory Type 1 cells for clinical application","volume":"9","author":"Gregori","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2021.102761_bb0030","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1172\/JCI82771","article-title":"Alloantigen-specific regulatory T cells generated with a chimeric antigen receptor","volume":"126","author":"MacDonald","year":"2016","journal-title":"J Clin Invest"},{"key":"10.1016\/j.autrev.2021.102761_bb0035","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/nm.3432","article-title":"Pathogenic conversion of Foxp3+ T cells into TH17 cells in autoimmune arthritis","volume":"20","author":"Komatsu","year":"2014","journal-title":"Nat Med"},{"key":"10.1016\/j.autrev.2021.102761_bb0040","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1093\/intimm\/dxp095","article-title":"Regulatory T cells: how do they suppress immune responses?","volume":"21","author":"Sakaguchi","year":"2009","journal-title":"International Immunology"},{"key":"10.1016\/j.autrev.2021.102761_bb0045","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.omtm.2019.11.022","article-title":"Genetic engineering of T cells for immune tolerance","volume":"16","author":"Scott","year":"2020","journal-title":"Molecular Therapy - Methods & Clinical Development"},{"key":"10.1016\/j.autrev.2021.102761_bb0050","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/nri2343","article-title":"How regulatory T cells work","volume":"8","author":"Vignali","year":"2008","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.autrev.2021.102761_bb0055","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/j.1365-2567.2008.02813.x","article-title":"Mechanisms of regulatory T-cell suppression - a diverse arsenal for a moving target","volume":"124","author":"Sojka","year":"2008","journal-title":"Immunology"},{"key":"10.1016\/j.autrev.2021.102761_bb0060","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3389\/fimmu.2012.00051","article-title":"Molecular mechanisms of treg-mediated T cell suppression","volume":"3","author":"Schmidt","year":"2012","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2021.102761_bb0065","doi-asserted-by":"crossref","first-page":"S38","DOI":"10.1016\/j.jisp.2016.10.023","article-title":"Cells to Halt depigmentation in vitiligo","volume":"18","author":"Le Poole","year":"2017","journal-title":"J Investig Dermatol Symp Proc"},{"key":"10.1016\/j.autrev.2021.102761_bb0070","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1038\/ni.3731","article-title":"The multiple pathways to autoimmunity","volume":"18","author":"Theofilopoulos","year":"2017","journal-title":"Nat Immunol"},{"issue":"2019","key":"10.1016\/j.autrev.2021.102761_bb0075","article-title":"Tyrosine kinases in autoimmune and inflammatory skin diseases","volume":"10","author":"Szilveszter","year":"1862","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2021.102761_bb0080","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ijwd.2017.11.004","article-title":"Psychosocial impact of inherited and autoimmune blistering diseases","volume":"4","author":"Jain","year":"2018","journal-title":"Int J Womens Dermatol"},{"key":"10.1016\/j.autrev.2021.102761_bb0085","doi-asserted-by":"crossref","first-page":"389","DOI":"10.5021\/ad.2010.22.4.389","article-title":"Impact of psoriasis on quality of life: relationship between clinical response to therapy and change in health-related quality of life","volume":"22","author":"Lee","year":"2010","journal-title":"Ann Dermatol"},{"key":"10.1016\/j.autrev.2021.102761_bb0090","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/j.1365-2133.2009.09091.x","article-title":"Willingness-to-pay and quality of life in patients with vitiligo","volume":"161","author":"Radtke","year":"2009","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.autrev.2021.102761_bb0095","first-page":"2789242","article-title":"Genetic factors of autoimmune diseases","author":"Ceccarelli","year":"2017","journal-title":"J Immunol Res"},{"key":"10.1016\/j.autrev.2021.102761_bb0100","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/jhg.2015.94","article-title":"Genetics of autoimmune diseases: insights from population genetics","volume":"60","author":"Ramos","year":"2015","journal-title":"Journal of Human Genetics"},{"key":"10.1016\/j.autrev.2021.102761_bb0105","doi-asserted-by":"crossref","first-page":"v","DOI":"10.1016\/j.coi.2014.10.010","article-title":"Editorial overview: autoimmunity","volume":"31","author":"Jabri","year":"2014","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.autrev.2021.102761_bb0110","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1111\/j.1365-4632.2011.05377.x","article-title":"A review of the worldwide prevalence of vitiligo in children\/adolescents and adults","volume":"51","author":"Kruger","year":"2012","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.autrev.2021.102761_bb0115","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1038\/jid.2009.32","article-title":"Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients","volume":"129","author":"van den Boorn","year":"2009","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.autrev.2021.102761_bb0120","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1084\/jem.190.5.705","article-title":"High frequencies of naive Melan-A\/MART-1-specific CD8(+) T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals","volume":"190","author":"Pittet","year":"1999","journal-title":"J Exp Med"},{"key":"10.1016\/j.autrev.2021.102761_bb0125","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1046\/j.1365-2249.2002.01949.x","article-title":"Autoantibodies in vitiligo patients are not directed to the melanocyte differentiation antigen MelanA\/MART1","volume":"129","author":"Waterman","year":"2002","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.autrev.2021.102761_bb0130","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1084\/jem.188.6.1203","article-title":"High frequency of skin-homing melanocyte-specific cytotoxic T lymphocytes in autoimmune vitiligo","volume":"188","author":"Ogg","year":"1998","journal-title":"J Exp Med"},{"key":"10.1016\/j.autrev.2021.102761_bb0135","first-page":"2630","article-title":"X. Hu and J. Xu, [Study of immunomodulatory function of exosomes derived from human umbilical cord mesenchymal stem cells]","volume":"95","author":"Liu","year":"2015","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"10.1016\/j.autrev.2021.102761_bb0140","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/jmedgenet-2018-105439","article-title":"Exosomes derived from exhausted CD8+ T cells impaired the anticancer function of normal CD8+ T cells","volume":"56","author":"Wang","year":"2019","journal-title":"J Med Genet"},{"key":"10.1016\/j.autrev.2021.102761_bb0145","doi-asserted-by":"crossref","first-page":"102664","DOI":"10.1016\/j.autrev.2020.102664","article-title":"New insight into the role of exosomes in vitiligo","volume":"19","author":"Wong","year":"2020","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2021.102761_bb0150","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/j.1755-148X.2011.00916.x","article-title":"HSP70i is a critical component of the immune response leading to vitiligo","volume":"25","author":"Mosenson","year":"2012","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.autrev.2021.102761_bb0155","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1111\/exd.12183","article-title":"A central role for inducible heat-shock protein 70 in autoimmune vitiligo","volume":"22","author":"Mosenson","year":"2013","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.autrev.2021.102761_bb0160","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/j.1755-148X.2010.00688.x","article-title":"Reduced skin homing by functional Treg in vitiligo","volume":"23","author":"Klarquist","year":"2010","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.autrev.2021.102761_bb0165","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1111\/pcmr.12284","article-title":"Immune responses in a mouse model of vitiligo with spontaneous epidermal de- and repigmentation","volume":"27","author":"Eby","year":"2014","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.autrev.2021.102761_bb0170","doi-asserted-by":"crossref","first-page":"e37513","DOI":"10.1371\/journal.pone.0037513","article-title":"Global activation of CD8+ cytotoxic T lymphocytes correlates with an impairment in regulatory T cells in patients with generalized vitiligo","volume":"7","author":"Lili","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.autrev.2021.102761_bb0175","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1111\/pcmr.12105","article-title":"Decreased regulatory T-cells and CD4(+) \/CD8(+) ratio correlate with disease onset and progression in patients with generalized vitiligo","volume":"26","author":"Dwivedi","year":"2013","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.autrev.2021.102761_bb0180","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1084\/jem.193.11.1295","article-title":"Human cd25(+)cd4(+) t regulatory cells suppress naive and memory T cell proliferation and can be expanded in vitro without loss of function","volume":"193","author":"Levings","year":"2001","journal-title":"J Exp Med"},{"key":"10.1016\/j.autrev.2021.102761_bb0185","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/j.1755-148X.2011.00920.x","article-title":"Functional defects of peripheral regulatory T lymphocytes in patients with progressive vitiligo","volume":"25","author":"Ben Ahmed","year":"2012","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.autrev.2021.102761_bb0190","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1111\/ijd.12160","article-title":"Assessment of tissue FoxP3+, CD4+ and CD8+ T-cells in active and stable nonsegmental vitiligo","volume":"53","author":"Abdallah","year":"2014","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.autrev.2021.102761_bb0195","doi-asserted-by":"crossref","first-page":"329","DOI":"10.2340\/00015555-1713","article-title":"Coexistent skin lesions of vitiligo and psoriasis vulgaris. Immunohistochemical analyses for IL-17A-producing cells and regulatory T cells","volume":"94","author":"Ono","year":"2014","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.autrev.2021.102761_bb0200","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1111\/j.1755-148X.2012.01019.x","article-title":"Systemic analyses of immunophenotypes of peripheral T cells in non-segmental vitiligo: implication of defective natural killer T cells","volume":"25","author":"Zhou","year":"2012","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.autrev.2021.102761_bb0205","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/j.1365-4632.2012.05808.x","article-title":"Immunohistochemical analysis of FOXP3+ regulatory T cells in healthy human skin and autoimmune dermatoses","volume":"53","author":"Terras","year":"2014","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.autrev.2021.102761_bb0210","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s00005-006-0035-x","article-title":"Induction and maintenance of self tolerance: the role of CD4+CD25+ regulatory T cells","volume":"54","author":"Bala","year":"2006","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"key":"10.1016\/j.autrev.2021.102761_bb0215","doi-asserted-by":"crossref","first-page":"4183","DOI":"10.4049\/jimmunol.169.8.4183","article-title":"Generation ex vivo of TGF-beta-producing regulatory T cells from CD4+CD25- precursors","volume":"169","author":"Zheng","year":"2002","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2021.102761_bb0220","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.jaad.2011.07.018","article-title":"Circulatory levels of T-cell cytokines (interleukin [IL]-2, IL-4, IL-17, and transforming growth factor-beta) in patients with vitiligo","author":"Khan","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.autrev.2021.102761_bb0225","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1034\/j.1600-0749.2002.1o049.x","article-title":"New insights into the pathogenesis of vitiligo: imbalance of epidermal cytokines at sites of lesions","volume":"15","author":"Moretti","year":"2002","journal-title":"Pigment Cell Res"},{"key":"10.1016\/j.autrev.2021.102761_bb0230","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.cca.2013.05.005","article-title":"T helper and regulatory T cell cytokine profile in active, stable and narrow band ultraviolet B treated generalized vitiligo","volume":"424","author":"Tembhre","year":"2013","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.autrev.2021.102761_bb0235","first-page":"423490","article-title":"Association of IFN-\u03b3: IL-10 cytokine ratio with nonsegmental vitiligo pathogenesis","author":"Ala","year":"2015","journal-title":"Autoimmune Dis"},{"key":"10.1016\/j.autrev.2021.102761_bb0240","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1172\/JCI3335","article-title":"Identification and characterization of autoreactive T cell responses to bullous pemphigoid antigen 2 in patients and healthy controls","volume":"102","author":"Budinger","year":"1998","journal-title":"J Clin Invest"},{"key":"10.1016\/j.autrev.2021.102761_bb0245","doi-asserted-by":"crossref","first-page":"978","DOI":"10.3389\/fimmu.2019.00978","article-title":"Current clinical trials in pemphigus and pemphigoid","volume":"10","author":"Izumi","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2021.102761_bb0250","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1007\/s00403-012-1213-9","article-title":"Circulating CD4+ CD25brightFOXP3+ regulatory T-cells are significantly reduced in bullous pemphigoid patients","volume":"304","author":"Quaglino","year":"2012","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.autrev.2021.102761_bb0255","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/jdv.12091","article-title":"Regulatory T cells in skin lesions and blood of patients with bullous pemphigoid","volume":"28","author":"Antiga","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.autrev.2021.102761_bb0260","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1111\/j.1600-0625.2011.01378.x","article-title":"Lesional Th17 cells and regulatory T cells in bullous pemphigoid","volume":"20","author":"Arakawa","year":"2011","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.autrev.2021.102761_bb0265","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/j.1600-0625.2006.00522.x","article-title":"Frequency, function and CLA expression of CD4+CD25+FOXP3+ regulatory T cells in bullous pemphigoid","volume":"16","author":"Rensing-Ehl","year":"2007","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.autrev.2021.102761_bb0270","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.3389\/fimmu.2017.01628","article-title":"Cells suppress inflammation and blistering in pemphigoid diseases","volume":"8","author":"Bieber","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2021.102761_bb0275","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1159\/000099585","article-title":"CD4+CD25high regulatory T cells are markedly decreased in blood of patients with pemphigus vulgaris","volume":"214","author":"Sugiyama","year":"2007","journal-title":"Dermatology"},{"key":"10.1016\/j.autrev.2021.102761_bb0280","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.4049\/jimmunol.176.5.3215","article-title":"Inhibition of the transcription factor Foxp3 converts desmoglein 3-specific type 1 regulatory T cells into Th2-Like cells","volume":"176","author":"Veldman","year":"2006","journal-title":"The Journal of Immunology"},{"key":"10.1016\/j.autrev.2021.102761_bb0285","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/intimm\/dxr020","article-title":"Antigen-independent development of Foxp3+ regulatory T cells suppressing autoantibody production in experimental pemphigus vulgaris","volume":"23","author":"Yokoyama","year":"2011","journal-title":"Int Immunol"},{"key":"10.1016\/j.autrev.2021.102761_bb0290","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/exd.12919","article-title":"Induction of T regulatory cells by the superagonistic anti-CD28 antibody D665 leads to decreased pathogenic IgG autoantibodies against desmoglein 3 in a HLA-transgenic mouse model of pemphigus vulgaris","volume":"25","author":"Schmidt","year":"2016","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.autrev.2021.102761_bb0295","doi-asserted-by":"crossref","first-page":"3.27.1","DOI":"10.1002\/0471142735.im0327s113","article-title":"Differentiation and characterization of Tr1 cells","volume":"113","author":"Chihara","year":"2016","journal-title":"Current Protocols in Immunology"},{"key":"10.1016\/j.autrev.2021.102761_bb0300","doi-asserted-by":"crossref","first-page":"6468","DOI":"10.4049\/jimmunol.172.10.6468","article-title":"Type I regulatory T cells specific for desmoglein 3 are more frequently detected in healthy individuals than in patients with pemphigus vulgaris","volume":"172","author":"Veldman","year":"2004","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2021.102761_bb0305","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.clindermatol.2007.08.013","article-title":"Resident skin cells in psoriasis: a special look at the pathogenetic functions of keratinocytes","volume":"25","author":"Albanesi","year":"2007","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.autrev.2021.102761_bb0310","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1038\/jid.2009.59","article-title":"The IL-23\/Th17 axis in the immunopathogenesis of psoriasis","volume":"129","author":"Di Cesare","year":"2009","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.autrev.2021.102761_bb0315","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/j.1365-2230.2010.03972.x","article-title":"Role of interleukin-17 in the pathogenesis of vitiligo","volume":"36","author":"Bassiouny","year":"2011","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.autrev.2021.102761_bb0320","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.cytogfr.2019.01.001","article-title":"Emerging role of immune cell network in autoimmune skin disorders: An update on pemphigus, vitiligo and psoriasis","volume":"45","author":"Das","year":"2019","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1016\/j.autrev.2021.102761_bb0325","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.jaad.2016.12.005","article-title":"JAK inhibitors in dermatology: the promise of a new drug class","volume":"76","author":"Damsky","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.autrev.2021.102761_bb0330","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1002\/ccr3.2759","article-title":"Effective use of oral tofacitinib and phototherapy in a patient with concomitant alopecia areata, vitiligo, and plaque and inverse psoriasis","author":"Tajalli","year":"2020","journal-title":"Clin Case Rep"},{"key":"10.1016\/j.autrev.2021.102761_bb0335","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1097\/DSS.0000000000000485","article-title":"Applications of the Excimer Laser: A Review","volume":"41","author":"Beggs","year":"2015","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.autrev.2021.102761_bb0340","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1084\/jem.20090480","article-title":"Self-RNA-antimicrobial peptide complexes activate human dendritic cells through TLR7 and TLR8","volume":"206","author":"Ganguly","year":"2009","journal-title":"J Exp Med"},{"key":"10.1016\/j.autrev.2021.102761_bb0345","doi-asserted-by":"crossref","first-page":"5","DOI":"10.2340\/00015555-2808","article-title":"Highlighting interleukin-36 signalling in plaque psoriasis and pustular psoriasis","volume":"98","author":"Furue","year":"2018","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.autrev.2021.102761_bb0350","doi-asserted-by":"crossref","first-page":"236","DOI":"10.5455\/medarh.2014.68.236-238","article-title":"Immunophenotype lymphocyte of peripheral blood in patients with psoriasis","volume":"68","author":"Karamehic","year":"2014","journal-title":"Med Arch"},{"key":"10.1016\/j.autrev.2021.102761_bb0355","doi-asserted-by":"crossref","first-page":"397","DOI":"10.5021\/ad.2010.22.4.397","article-title":"Role of CD4CD25FOXP3 regulatory T cells in psoriasis","volume":"22","author":"Yun","year":"2010","journal-title":"Ann Dermatol"},{"key":"10.1016\/j.autrev.2021.102761_bb0360","doi-asserted-by":"crossref","first-page":"164","DOI":"10.4049\/jimmunol.174.1.164","article-title":"Dysfunctional blood and target tissue CD4+CD25high regulatory T cells in psoriasis: mechanism underlying unrestrained pathogenic effector T cell proliferation","volume":"174","author":"Sugiyama","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2021.102761_bb0365","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.jdermsci.2015.11.007","article-title":"Impaired function of regulatory T cells in patients with psoriasis is mediated by phosphorylation of STAT3","volume":"81","author":"Yang","year":"2016","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.autrev.2021.102761_bb0370","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1038\/jid.2011.139","article-title":"Foxp3+ regulatory T cells of psoriasis patients easily differentiate into IL-17A-producing cells and are found in lesional skin","volume":"131","author":"Bovenschen","year":"2011","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.autrev.2021.102761_bb0375","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1111\/bjd.12236","article-title":"Balance of Treg vs. T-helper cells in the transition from symptomless to lesional psoriatic skin","volume":"168","author":"Keijsers","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.autrev.2021.102761_bb0380","doi-asserted-by":"crossref","first-page":"3564","DOI":"10.1016\/j.celrep.2018.12.012","article-title":"Regulatory T cells restrain pathogenic T helper cells during skin inflammation","volume":"e4","author":"Hartwig","year":"2018","journal-title":"Cell Rep 25"},{"key":"10.1016\/j.autrev.2021.102761_bb0385","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1084\/jem.20172094","article-title":"Foxp3(+) T reg cells control psoriasiform inflammation by restraining an IFN-I-driven CD8(+) T cell response","volume":"215","author":"Stockenhuber","year":"2018","journal-title":"J Exp Med"},{"key":"10.1016\/j.autrev.2021.102761_bb0390","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1002\/path.4786","article-title":"Macrophage-mediated psoriasis can be suppressed by regulatory T lymphocytes","volume":"240","author":"Leite Dantas","year":"2016","journal-title":"J Pathol"},{"key":"10.1016\/j.autrev.2021.102761_bb0395","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1172\/JCI34916","article-title":"TGF-beta-dependent suppressive function of Tregs requires wild-type levels of CD18 in a mouse model of psoriasis","volume":"118","author":"Wang","year":"2008","journal-title":"J Clin Invest"},{"key":"10.1016\/j.autrev.2021.102761_bb0400","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1038\/jidsymp.2013.7","article-title":"The role of hair follicle immune privilege collapse in alopecia areata: status and perspectives","volume":"16","author":"Paus","year":"2013","journal-title":"J Investig Dermatol Symp Proc"},{"key":"10.1016\/j.autrev.2021.102761_bb0405","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1111\/1523-1747.ep12395722","article-title":"Cytokine mRNA levels in Alopecia areata before and after treatment with the contact allergen diphenylcyclopropenone","volume":"103","author":"Hoffmann","year":"1994","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.autrev.2021.102761_bb0410","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1189\/jlb.0413196","article-title":"Tolerance induction by hair-specific keratins in murine alopecia areata","volume":"94","author":"Erb","year":"2013","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.autrev.2021.102761_bb0415","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1046\/j.1523-1747.2002.01745.x","article-title":"Transient CD44 variant isoform expression and reduction in CD4(+)\/CD25(+) regulatory T cells in C3H\/HeJ mice with alopecia areata","volume":"118","author":"Zoller","year":"2002","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.autrev.2021.102761_bb0420","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1111\/j.0022-202X.2005.23692.x","article-title":"Transfer of CD8(+) cells induces localized hair loss whereas CD4(+)\/CD25(-) cells promote systemic alopecia areata and CD4(+)\/CD25(+) cells blockade disease onset in the C3H\/HeJ mouse model","volume":"124","author":"McElwee","year":"2005","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.autrev.2021.102761_bb0425","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/cup.13479","article-title":"Regulatory T-cells in alopecia areata","volume":"46","author":"Speiser","year":"2019","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.autrev.2021.102761_bb0430","doi-asserted-by":"crossref","first-page":"e0210308","DOI":"10.1371\/journal.pone.0210308","article-title":"Alopecia areata patients show deficiency of FOXP3+CD39+ T regulatory cells and clonotypic restriction of Treg TCRbeta-chain, which highlights the immunopathological aspect of the disease","volume":"14","author":"Hamed","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.autrev.2021.102761_bb0435","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1001\/jamadermatol.2014.504","article-title":"Effects of low-dose recombinant interleukin 2 to promote T-regulatory cells in alopecia areata","volume":"150","author":"Castela","year":"2014","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.autrev.2021.102761_bb0440","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/nature09114","article-title":"Genome-wide association study in alopecia areata implicates both innate and adaptive immunity","volume":"466","author":"Petukhova","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.autrev.2021.102761_bb0445","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1111\/bjd.12396","article-title":"T-helper and regulatory T-cell cytokines in the peripheral blood of patients with active alopecia areata","volume":"169","author":"Tembhre","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.autrev.2021.102761_bb0450","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1111\/jdv.14775","article-title":"Role of T helper 17 cells and T regulatory cells in alopecia areata: comparison of lesion and serum cytokine between controls and patients","volume":"32","author":"Loh","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.autrev.2021.102761_bb0455","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jdermsci.2013.01.006","article-title":"Impaired inhibitory function of circulating CD4+CD25+ regulatory T cells in alopecia areata","volume":"70","author":"Shin","year":"2013","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.autrev.2021.102761_bb0460","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1111\/1346-8138.13432","article-title":"Case of disseminated granuloma annulare with giant plaques","volume":"43","author":"Saigusa","year":"2016","journal-title":"J Dermatol"},{"key":"10.1016\/j.autrev.2021.102761_bb0465","doi-asserted-by":"crossref","first-page":"272","DOI":"10.3389\/fimmu.2015.00272","article-title":"Pathogenesis of systemic sclerosis","volume":"6","author":"Pattanaik","year":"2015","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2021.102761_bb0470","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1136\/annrheumdis-2011-200709","article-title":"Activated and resting regulatory T cell exhaustion concurs with high levels of interleukin-22 expression in systemic sclerosis lesions","volume":"71","author":"Mathian","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2021.102761_bb0475","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1080\/08916930802282651","article-title":"Quantification and molecular characterization of regulatory T cells in connective tissue diseases","volume":"42","author":"Banica","year":"2009","journal-title":"Autoimmunity"},{"key":"10.1016\/j.autrev.2021.102761_bb0480","doi-asserted-by":"crossref","first-page":"e64531","DOI":"10.1371\/journal.pone.0064531","article-title":"Elevated levels of CD4(+)CD25(+)FoxP3(+) T cells in systemic sclerosis patients contribute to the secretion of IL-17 and immunosuppression dysfunction","volume":"8","author":"Liu","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.autrev.2021.102761_bb0485","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.clim.2011.01.013","article-title":"Alteration of Th17 and Treg cell subpopulations co-exist in patients affected with systemic sclerosis","volume":"139","author":"Fenoglio","year":"2011","journal-title":"Clin Immunol"},{"key":"10.1016\/j.autrev.2021.102761_bb0490","first-page":"390563","article-title":"Assessment of T regulatory cells and expanded profiling of autoantibodies may offer novel biomarkers for the clinical management of systemic sclerosis and undifferentiated connective tissue disease","author":"Cordiali-Fei","year":"2013","journal-title":"Clin Dev Immunol"},{"key":"10.1016\/j.autrev.2021.102761_bb0495","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/bjd.12913","article-title":"DNA hypermethylation of the forkhead box protein 3 (FOXP3) promoter in CD4+ T cells of patients with systemic sclerosis","volume":"171","author":"Wang","year":"2014","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.autrev.2021.102761_bb0500","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/bmt.2013.202","article-title":"Peripheral blood regulatory T cells in patients with diffuse systemic sclerosis (SSc) before and after autologous hematopoietic SCT: a pilot study","volume":"49","author":"Baraut","year":"2014","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.autrev.2021.102761_bb0505","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1136\/ard.2009.116525","article-title":"Reduction of regulatory T cells in skin lesions but not in peripheral blood of patients with systemic scleroderma","volume":"70","author":"Klein","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2021.102761_bb0510","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1111\/j.1365-2133.2010.09633.x","article-title":"Regulatory T cells in the skin lesions and blood of patients with systemic sclerosis and morphoea","volume":"162","author":"Antiga","year":"2010","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.autrev.2021.102761_bb0515","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.cellimm.2009.12.009","article-title":"Regulatory T cells (CD4(+)CD25(bright)FoxP3(+)) expansion in systemic sclerosis correlates with disease activity and severity","volume":"261","author":"Slobodin","year":"2010","journal-title":"Cell Immunol"},{"key":"10.1016\/j.autrev.2021.102761_bb0520","doi-asserted-by":"crossref","first-page":"90","DOI":"10.3109\/14397595.2014.899736","article-title":"Decreased expression of Runx1 and lowered proportion of Foxp3(+) CD25(+) CD4(+) regulatory T cells in systemic sclerosis","volume":"25","author":"Kataoka","year":"2015","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.autrev.2021.102761_bb0525","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.clim.2017.05.013","article-title":"Increased proportions of functionally impaired regulatory T cell subsets in systemic sclerosis","volume":"184","author":"Ugor","year":"2017","journal-title":"Clin Immunol"},{"key":"10.1016\/j.autrev.2021.102761_bb0530","doi-asserted-by":"crossref","first-page":"205","DOI":"10.3109\/03009742.2010.528021","article-title":"Altered T-cell and regulatory cell repertoire in patients with diffuse cutaneous systemic sclerosis","volume":"40","author":"Papp","year":"2011","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.autrev.2021.102761_bb0535","doi-asserted-by":"crossref","first-page":"R4","DOI":"10.1186\/ar4430","article-title":"Increased frequency of Th17 cells in systemic sclerosis is related to disease activity and collagen overproduction","volume":"16","author":"Yang","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2021.102761_bb0540","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2014.12.1932","article-title":"Regulatory T cells produce profibrotic cytokines in the skin of patients with systemic sclerosis","volume":"135","author":"MacDonald","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.autrev.2021.102761_bb0545","doi-asserted-by":"crossref","first-page":"179ra43","DOI":"10.1126\/scitranslmed.3005265","article-title":"Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease","volume":"5","author":"Matsuoka","year":"2013","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.autrev.2021.102761_bb0550","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1182\/bloodadvances.2017011072","article-title":"Immune rebound associates with a favorable clinical response to autologous HSCT in systemic sclerosis patients","volume":"2","author":"Arruda","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.autrev.2021.102761_bb0555","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s12931-018-0783-2","article-title":"Resolution of bleomycin-induced murine pulmonary fibrosis via a splenic lymphocyte subpopulation","volume":"19","author":"Kamio","year":"2018","journal-title":"Respir Res"},{"key":"10.1016\/j.autrev.2021.102761_bb0560","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.imbio.2012.05.020","article-title":"Differential role of regulatory T cells in early and late stages of pulmonary fibrosis","volume":"218","author":"Boveda-Ruiz","year":"2013","journal-title":"Immunobiology"},{"key":"10.1016\/j.autrev.2021.102761_bb0565","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1172\/JCI77958","article-title":"Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients","volume":"125","author":"Rice","year":"2015","journal-title":"J Clin Invest"},{"key":"10.1016\/j.autrev.2021.102761_bb0570","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.4049\/jimmunol.1103271","article-title":"A coreceptor-independent transgenic human TCR mediates anti-tumor and anti-self immunity in mice","volume":"189","author":"Mehrotra","year":"2012","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2021.102761_bb0575","doi-asserted-by":"crossref","first-page":"5733","DOI":"10.4049\/jimmunol.1301769","article-title":"Functional comparison of engineered T cells carrying a native TCR versus TCR-like antibody-based chimeric antigen receptors indicates affinity\/avidity thresholds","volume":"193","author":"Oren","year":"2014","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2021.102761_bb0580","doi-asserted-by":"crossref","first-page":"3619","DOI":"10.1172\/JCI33185","article-title":"Conferring indirect allospecificity on CD4+CD25+ Tregs by TCR gene transfer favors transplantation tolerance in mice","volume":"118","author":"Tsang","year":"2008","journal-title":"J Clin Invest"},{"key":"10.1016\/j.autrev.2021.102761_bb0585","doi-asserted-by":"crossref","first-page":"102289","DOI":"10.1016\/j.jaut.2019.05.017","article-title":"Regulatory T cells engineered with a novel insulin-specific chimeric antigen receptor as a candidate immunotherapy for type 1 diabetes","volume":"103","author":"Tenspolde","year":"2019","journal-title":"Journal of Autoimmunity"},{"key":"10.1016\/j.autrev.2021.102761_bb0590","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1182\/blood-2016-07-727834","article-title":"FVIII-specific human chimeric antigen receptor T-regulatory cells suppress T- and B-cell responses to FVIII","volume":"129","author":"Yoon","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2021.102761_bb0595","first-page":"2","article-title":"Low-dose IL-2 therapy for autoimmune diseases","volume":"15","author":"Collison","year":"2019","journal-title":"Nature Reviews Rheumatology"},{"key":"10.1016\/j.autrev.2021.102761_bb0600","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.4049\/jimmunol.1900733","article-title":"Low-Dose IL-2 therapy in transplantation, autoimmunity, and inflammatory diseases","volume":"203","author":"Tahvildari","year":"2019","journal-title":"The Journal of Immunology"},{"key":"10.1016\/j.autrev.2021.102761_bb0605","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1136\/annrheumdis-2018-214229","article-title":"Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial","volume":"78","author":"Rosenzwajg","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2021.102761_bb0610","doi-asserted-by":"crossref","first-page":"102645","DOI":"10.1016\/j.autrev.2020.102645","article-title":"Low-dose Interleukin-2: Biology and therapeutic prospects in rheumatoid arthritis","volume":"19","author":"Wu","year":"2020","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2021.102761_bb0615","doi-asserted-by":"crossref","first-page":"7797","DOI":"10.1073\/pnas.0800928105","article-title":"T cell receptor signaling controls Foxp3 expression via PI3K, Akt, and mTOR","volume":"105","author":"Sauer","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.autrev.2021.102761_bb0620","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1136\/gutjnl-2012-303635","article-title":"Autoimmune pancreatitis in MRL\/Mp mice is a T cell-mediated disease responsive to cyclosporine A and rapamycin treatment","volume":"63","author":"Schwaiger","year":"2014","journal-title":"Gut"},{"key":"10.1016\/j.autrev.2021.102761_bb0625","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1097\/SAP.0b013e31826956f6","article-title":"Transcriptional profiling of rapamycin-treated fibroblasts from hypertrophic and keloid scars","volume":"72","author":"Wong","year":"2014","journal-title":"Ann Plast Surg"},{"key":"10.1016\/j.autrev.2021.102761_bb0630","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/dth.12176","article-title":"Combination of everolimus and tacrolimus: a potentially effective regimen for recalcitrant psoriasis","volume":"28","author":"Wei","year":"2015","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.autrev.2021.102761_bb0635","doi-asserted-by":"crossref","first-page":"276","DOI":"10.4274\/jcrpe.2766","article-title":"Vitamin D status in children with chronic autoimmune thyroiditis","volume":"8","author":"Siklar","year":"2016","journal-title":"J Clin Res Pediatr Endocrinol"},{"key":"10.1016\/j.autrev.2021.102761_bb0640","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1038\/jid.2015.26","article-title":"CCL22 to activate treg migration and suppress depigmentation in vitiligo","volume":"135","author":"Eby","year":"2015","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.autrev.2021.102761_bb0645","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1016\/j.jid.2018.06.186","article-title":"HSP70iQ435A-encoding DNA repigments vitiligo lesions in sinclair swine","volume":"138","author":"Henning","year":"2018","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.autrev.2021.102761_bb0650","doi-asserted-by":"crossref","first-page":"6230","DOI":"10.1158\/0008-5472.CAN-16-0618","article-title":"Ccl22 diverts T regulatory cells and controls the growth of melanoma","volume":"76","author":"Klarquist","year":"2016","journal-title":"Cancer research"},{"key":"10.1016\/j.autrev.2021.102761_bb0655","doi-asserted-by":"crossref","first-page":"261","DOI":"10.4161\/gmic.20358","article-title":"Portrait of an immunoregulatory Bifidobacterium","volume":"3","author":"Konieczna","year":"2012","journal-title":"Gut Microbes"},{"key":"10.1016\/j.autrev.2021.102761_bb0660","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1136\/gutjnl-2011-300936","article-title":"L. O\u2019Mahony, Bifidobacterium infantis 35624 administration induces Foxp3 T regulatory cells in human peripheral blood: potential role for myeloid and plasmacytoid dendritic cells","volume":"61","author":"Konieczna","year":"2012","journal-title":"Gut"},{"key":"10.1016\/j.autrev.2021.102761_bb0665","doi-asserted-by":"crossref","first-page":"e1000112","DOI":"10.1371\/journal.ppat.1000112","article-title":"Commensal-induced regulatory T cells mediate protection against pathogen-stimulated NF-kappaB activation","volume":"4","author":"O'Mahony","year":"2008","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.autrev.2021.102761_bb0670","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.jid.2019.08.435","article-title":"Antibiotics drive microbial imbalance and vitiligo development in mice","volume":"140","author":"Dellacecca","year":"2019","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.autrev.2021.102761_bb0675","doi-asserted-by":"crossref","first-page":"304ps18","DOI":"10.1126\/scitranslmed.aaa7721","article-title":"Hurdles in therapy with regulatory T cells","volume":"7","author":"Trzonkowski","year":"2015","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.autrev.2021.102761_bb0680","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/j.bbmt.2013.06.004","article-title":"Adoptive transfer of umbilical cord blood-derived regulatory T cells and early viral reactivation","volume":"19","author":"Brunstein","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.autrev.2021.102761_bb0685","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1084\/jem.20040139","article-title":"In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes","volume":"199","author":"Tang","year":"2004","journal-title":"J Exp Med"},{"key":"10.1016\/j.autrev.2021.102761_bb0690","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1084\/jem.20040180","article-title":"CD25+ CD4+ T cells, expanded with dendritic cells presenting a single autoantigenic peptide, suppress autoimmune diabetes","volume":"199","author":"Tarbell","year":"2004","journal-title":"J Exp Med"},{"key":"10.1016\/j.autrev.2021.102761_bb0695","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.4049\/jimmunol.175.5.3053","article-title":"Expansion of functional endogenous antigen-specific CD4+CD25+ regulatory T cells from nonobese diabetic mice","volume":"175","author":"Masteller","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2021.102761_bb0700","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1002\/eji.200839073","article-title":"Curing CNS autoimmune disease with myelin-reactive Foxp3+ Treg","volume":"39","author":"Stephens","year":"2009","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.autrev.2021.102761_bb0705","doi-asserted-by":"crossref","first-page":"329","DOI":"10.4049\/jimmunol.176.1.329","article-title":"Specificity of CD4+CD25+ regulatory T cell function in alloimmunity","volume":"176","author":"Sanchez-Fueyo","year":"2006","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2021.102761_bb0710","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1093\/intimm\/dxh122","article-title":"Induction of antigen-specific immunologic tolerance by in vivo and in vitro antigen-specific expansion of naturally arising Foxp3+CD25+CD4+ regulatory T cells","volume":"16","author":"Nishimura","year":"2004","journal-title":"Int Immunol"},{"key":"10.1016\/j.autrev.2021.102761_bb0715","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/nm1688","article-title":"Prevention of acute and chronic allograft rejection with CD4+CD25+Foxp3+ regulatory T lymphocytes","volume":"14","author":"Joffre","year":"2008","journal-title":"Nat Med"},{"key":"10.1016\/j.autrev.2021.102761_bb0720","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1182\/blood-2006-05-025460","article-title":"In vitro-expanded donor alloantigen-specific CD4+CD25+ regulatory T cells promote experimental transplantation tolerance","volume":"109","author":"Golshayan","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2021.102761_bb0725","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1042\/BST20150247","article-title":"Antigen-specificity using chimeric antigen receptors: the future of regulatory T-cell therapy?","volume":"44","author":"Boardman","year":"2016","journal-title":"Biochem Soc Trans"},{"key":"10.1016\/j.autrev.2021.102761_bb0730","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/imr.12131","article-title":"Design and development of therapies using chimeric antigen receptor-expressing T cells","volume":"257","author":"Dotti","year":"2014","journal-title":"Immunol Rev"},{"key":"10.1016\/j.autrev.2021.102761_bb0735","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/j.1365-2567.2008.03015.x","article-title":"T-cell receptor binding affinities and kinetics: impact on T-cell activity and specificity","volume":"126","author":"Stone","year":"2009","journal-title":"Immunology"},{"key":"10.1016\/j.autrev.2021.102761_bb0740","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.tips.2015.11.004","article-title":"Cell therapies: a comparison of T cell receptors and chimeric antigen receptors","volume":"37","author":"Harris","year":"2016","journal-title":"Trends in pharmacological sciences"},{"key":"10.1016\/j.autrev.2021.102761_bb0745","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1007\/s11095-018-2436-z","article-title":"Chimeric antigen receptor T-cells (CAR T-Cells) for cancer immunotherapy - moving target for industry?","volume":"35","author":"Salmikangas","year":"2018","journal-title":"Pharm Res"},{"key":"10.1016\/j.autrev.2021.102761_bb0750","doi-asserted-by":"crossref","DOI":"10.1177\/1533033819831068","article-title":"The emerging world of TCR-T cell trials against cancer: a systematic review","volume":"18","author":"Zhang","year":"2019","journal-title":"Technol Cancer Res Treat"},{"key":"10.1016\/j.autrev.2021.102761_bb0755","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s13045-018-0568-6","article-title":"Chimeric antigen receptor T cell (CAR-T) immunotherapy for solid tumors: lessons learned and strategies for moving forward","volume":"11","author":"Li","year":"2018","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.autrev.2021.102761_bb0760","doi-asserted-by":"crossref","first-page":"315ra189","DOI":"10.1126\/scitranslmed.aad4134","article-title":"Type 1 diabetes immunotherapy using polyclonal regulatory T cells","volume":"7","author":"Bluestone","year":"2015","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.autrev.2021.102761_bb0765","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1111\/ajt.12433","article-title":"Clinical grade manufacturing of human alloantigen-reactive regulatory T cells for use in transplantation","volume":"13","author":"Putnam","year":"2013","journal-title":"Am J Transplant"},{"key":"10.1016\/j.autrev.2021.102761_bb0770","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1186\/s12967-016-1090-7","article-title":"Factors affecting long-term efficacy of T regulatory cell-based therapy in type 1 diabetes","volume":"14","author":"Marek-Trzonkowska","year":"2016","journal-title":"J Transl Med"},{"key":"10.1016\/j.autrev.2021.102761_bb0775","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.581433","article-title":"Antigen specificity enhances disease control by Tregs in vitiligo","volume":"11","author":"Mukhatayev","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.autrev.2021.102761_bb0780","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1126\/science.aaf6756","article-title":"Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease","volume":"353","author":"Ellebrecht","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.autrev.2021.102761_bb0785","doi-asserted-by":"crossref","first-page":"e92021","DOI":"10.1172\/jci.insight.92021","article-title":"Setting the target for pemphigus vulgaris therapy","volume":"2","author":"Ellebrecht","year":"2017","journal-title":"JCI Insight"},{"key":"10.1016\/j.autrev.2021.102761_bb0790","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.1038\/sj.onc.1206443","article-title":"Microphthalamia-associated transcription factor: a critical regulator of pigment cell development and survival","volume":"22","author":"Widlund","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.autrev.2021.102761_bb0795","doi-asserted-by":"crossref","first-page":"e11726","DOI":"10.1371\/journal.pone.0011726","article-title":"Human antigen-specific regulatory T cells generated by T cell receptor gene transfer","volume":"5","author":"Brusko","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.autrev.2021.102761_bb0800","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1046\/j.1365-2133.2003.05539.x","article-title":"Expansion of vitiligo lesions is associated with reduced epidermal CDw60 expression and increased expression of HLA-DR in perilesional skin","volume":"149","author":"Le Poole","year":"2003","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.autrev.2021.102761_bb0805","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.transci.2012.06.007","article-title":"T regulatory cell separation for clinical application","volume":"47","author":"Di Ianni","year":"2012","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.autrev.2021.102761_bb0810","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3389\/fimmu.2019.00038","article-title":"Automated clinical grade expansion of regulatory T cells in a fully closed system","volume":"10","author":"Mar\u00edn Morales","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2021.102761_bb0815","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.clim.2014.03.016","article-title":"Therapy of type 1 diabetes with CD4(+)CD25(high)CD127-regulatory T cells prolongs survival of pancreatic islets - results of one year follow-up","volume":"153","author":"Marek-Trzonkowska","year":"2014","journal-title":"Clin Immunol"},{"key":"10.1016\/j.autrev.2021.102761_bb0820","doi-asserted-by":"crossref","first-page":"652","DOI":"10.2337\/db08-1168","article-title":"Expansion of human regulatory T-cells from patients with type 1 diabetes","volume":"58","author":"Putnam","year":"2009","journal-title":"Diabetes"},{"key":"10.1016\/j.autrev.2021.102761_bb0825","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1136\/gutjnl-2014-306919","article-title":"Developing in vitro expanded CD45RA+ regulatory T cells as an adoptive cell therapy for Crohn\u2019s disease","volume":"65","author":"Canavan","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.autrev.2021.102761_bb0830","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1182\/blood-2014-03-564401","article-title":"HLA-haploidentical transplantation with regulatory and conventional T-cell adoptive immunotherapy prevents acute leukemia relapse","volume":"124","author":"Martelli","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2021.102761_bb0835","doi-asserted-by":"crossref","first-page":"e15868","DOI":"10.1371\/journal.pone.0015868","article-title":"Retinoic acid and rapamycin differentially affect and synergistically promote the ex vivo expansion of natural human T regulatory cells","volume":"6","author":"Golovina","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.autrev.2021.102761_bb0840","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.3324\/haematol.2012.074088","article-title":"Differential effects of rapamycin and retinoic acid on expansion, stability and suppressive qualities of human CD4(+)CD25(+)FOXP3(+) T regulatory cell subpopulations","volume":"98","author":"Scott\u00e0","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.autrev.2021.102761_bb0845","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.omtm.2018.01.006","article-title":"A Rapamycin-Based GMP-compatible process for the isolation and expansion of regulatory T cells for clinical trials","volume":"8","author":"Fraser","year":"2018","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.autrev.2021.102761_bb0850","doi-asserted-by":"crossref","first-page":"8338","DOI":"10.4049\/jimmunol.177.12.8338","article-title":"Rapamycin promotes expansion of functional CD4+CD25+FOXP3+ regulatory T cells of both healthy subjects and type 1 diabetic patients","volume":"177","author":"Battaglia","year":"2006","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2021.102761_bb0855","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1038\/nri2546","article-title":"Immunoregulatory functions of mTOR inhibition","volume":"9","author":"Thomson","year":"2009","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.autrev.2021.102761_bb0860","doi-asserted-by":"crossref","first-page":"7428","DOI":"10.1038\/s41598-018-25574-7","article-title":"A phase I Clinical trial with ex vivo expanded recipient regulatory T cells in living donor kidney transplants","volume":"8","author":"Mathew","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.autrev.2021.102761_bb0865","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/s41573-019-0041-4","article-title":"Next-generation regulatory T cell therapy","volume":"18","author":"Ferreira","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.autrev.2021.102761_bb0870","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.2337\/dc12-0038","article-title":"Administration of CD4+CD25highCD127- regulatory T cells preserves \u03b2-cell function in type 1 diabetes in children","volume":"35","author":"Marek-Trzonkowska","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.autrev.2021.102761_bb0875","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/pedi.12029","article-title":"Clinical application of regulatory T cells in type 1 diabetes","volume":"14","author":"Marek-Trzonkowska","year":"2013","journal-title":"Pediatr Diabetes"},{"key":"10.1016\/j.autrev.2021.102761_bb0880","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/s41577-019-0232-6","article-title":"T(reg) cell-based therapies: challenges and perspectives","volume":"20","author":"Raffin","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.autrev.2021.102761_bb0885","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1126\/science.aau2688","article-title":"T(reg) cells-the next frontier of cell therapy","volume":"362","author":"Bluestone","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.autrev.2021.102761_bb0890","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1172\/JCI17702","article-title":"Recipient-type specific CD4+CD25+ regulatory T cells favor immune reconstitution and control graft-versus-host disease while maintaining graft-versus-leukemia","volume":"112","author":"Trenado","year":"2003","journal-title":"J Clin Invest"},{"key":"10.1016\/j.autrev.2021.102761_bb0895","doi-asserted-by":"crossref","first-page":"83ra42","DOI":"10.1126\/scitranslmed.3002076","article-title":"Human regulatory T cells with alloantigen specificity are more potent inhibitors of alloimmune skin graft damage than polyclonal regulatory T cells","volume":"3","author":"Sagoo","year":"2011","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.autrev.2021.102761_bb0900","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1016\/j.transproceed.2013.01.073","article-title":"Donor-specific regulatory T cells generated on donor B cells are superior to CD4+CD25high cells in controlling alloimmune responses in humanized mice","volume":"45","author":"Noyan","year":"2013","journal-title":"Transplant Proc"},{"key":"10.1016\/j.autrev.2021.102761_bb0905","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.blre.2018.11.002","article-title":"Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management","volume":"34","author":"Brudno","year":"2019","journal-title":"Blood Rev"},{"key":"10.1016\/j.autrev.2021.102761_bb0910","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jaut.2018.02.006","article-title":"Engrafting human regulatory T cells with a flexible modular chimeric antigen receptor technology","volume":"90","author":"Koristka","year":"2018","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2021.102761_bb0915","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/j.jcyt.2019.10.011","article-title":"Cryopreservation timing is a critical process parameter in a thymic regulatory T-cell therapy manufacturing protocol","volume":"21","author":"MacDonald","year":"2019","journal-title":"Cytotherapy"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997221000203?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997221000203?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T21:20:35Z","timestamp":1761600035000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997221000203"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":183,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["S1568997221000203"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2021.102761","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Engineered antigen-specific regulatory T cells for autoimmune skin conditions","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2021.102761","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"102761"}}